US 2012/0065176 A1 · TREATMENT OF MUSCLE DISEASE CHARACTERIZED BY INSULIN RESISTANCE

Abstract

It is reported herein that certain muscle diseases and conditions, including forms of muscular dystrophy, are characterized by impaired insulin-dependent signaling in the muscle tissue, in essence, a form of insulin resistance. The present disclosure relates to therapeutic agents, compositions and methods for treating a muscle disease or condition characterized by impaired insulin-dependent signaling by targeting components of the defective insulin signaling pathway. The disease or condition may be treated by administering a therapeutic agent that activates the insulin signaling pathway, in particular, therapeutic agents that act post-insulin receptor to modulate intracellular effector molecules. An exemplary modulator is metformin. Metformin may be administered alone or may be co-administered with another therapeutic agent for treating the muscle disease or condition, such as a corticosteroid.

Claims22

Dependent claims

1-73. (canceled)

A compound having the structural formula of Formula II:

wherein:
R1 and R2 are independently selected from the group consisting of H, alkyl, alkoxy, haloalkyl, hydroxyalkyl, cyanoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl, alkylene-O-alkyl, alkylene-O-cycloalkyl, alkylene-O-heterocycloalkyl, alkylene-O-alkylene-cycloalkyl, alkylene-O-alkylene-heterocycloalkyl, C(O)-alkyl, C(O)-alkyl, C(O)-cycloalkyl, C(O)-cycloalkyl, C(O)-heterocycloalkyl, S(O)2-heterocycloalkyl, alkylene-O-aryl, alkylene-O-heteroaryl, alkylene-O-alkylene-aryl, alkylene-O-alkylene-heteroaryl, C(O)alkyl, OC(O)alkyl, C(O)Oalkyl, C(O)N(H)alkyl, C(O)N(alkyl)alkyl, S(O)2N(H)alkyl or S(O)2N(alkyl)alkyl;
R3 is selected from the group consisting of C1- to C8-lower alkyl, C1- to C8-lower alkoxy, C1- to C8-lower alkyl-ester, cycloalkyl, heterocycloalkyl, bicycloalkyl, heterobicycloalkyl, aryl, heteroaryl, optionally-substituted aryl, optionally-substituted hetero-aryl;
hydroxyalkyl, hydroxycycloalkyl, hydroxy-heterocycloalkyl, cyanoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, alkylaryl, alkylheteroaryl, alkylene-O-alkyl, alkylene-O-cycloalkyl, alkylene-O-heterocycloalkyl, alkylene-O-alkylene-cycloalkyl, alkylene-O-alkylene-heterocycloalkyl;
X is selected from the group consisting of lower-alkyl, O, C(O), C(O)2, C(O)N, S, S(O), S(O)2 and P(O)3;
and/or a pharmaceutically-acceptable salt, hydrate, solvate, isoform, tautomer, optical isomer, or combination thereof.

3 more elements

Dependencies are inferred from the claim text.

Treatment of muscle disease characterized by insulin resistance

Life of this patent

Treatment of muscle disease characterized by insulin resistance

Life of this patent

Abstract

Claims22